FIGURE 1.

a) Randomised controlled trial of danirixin (DNX) (n=14) versus placebo (n=5). Data are presented as median histone (H1)–elastase complexes (primary outcome) across the four trial visits. Note that this figure is generated from a post hoc analysis; the primary analysis was from the mixed model. b) Purified neutrophils from healthy donors (n=3) were stimulated with interleukin (IL)-8 (10 ng·mL⁻¹) or Gro-α (1000 nM) in the presence or absence of DNX (10 μM). % change in CD11b expression was determined by fluorescence-activated cell sorting analysis of mean fluorescent intensity (IL-8 paired t-test, p=0.0165; Gro-α paired t-test, p=0.0187). c) Neutrophil activation is blocked in response to DNX in some, but not all, COPD samples, independent of IL-8 sputum concentration; % reduction in CD11b expression after exposure of healthy volunteer neutrophils to 10% soluble sputum from patients with COPD in the presence of DNX (10 μM) against sputum IL-8 concentration (correlation, r=0.26, p=0.35). S: start of study; D1: day 1; D7: day 7; D14: day 14. *: p<0.05.